ABBV vs SYRE: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ABBV is the larger of the two ($509.92B market cap): the incumbent the market prices for continued execution (17.79x forward earnings, beta 0.19). SYRE is the smaller challenger ($8.98B), still expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, SYRE fits (beta 3.23). If you want the steadier ride, ABBV fits (beta 0.19).

ABBV vs SYRE: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricABBVSYREWhat it tells you
Market cap$509.92B$8.98BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E17.79-25.61Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.193.23Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range87% of range82% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how ABBV and SYRE affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABBV and SYRE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABBV and SYRE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does AbbVie (ABBV) do?

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.

Full ABBV guide

What does Spyre Therapeutics (SYRE) do?

Spyre Therapeutics (Nasdaq: SYRE) is a clinical-stage biotechnology company building extended half-life antibodies and antibody combinations aimed at inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and more recently the skin disease hidradenitis suppurativa (HS). Its lead programs target the TL1A pathway (SPY002 and SPY072) and complementary mechanisms such as alpha4beta7 (SPY001) and IL-23 (SPY003), engineered for less frequent dosing (potentially quarterly or twice-yearly) than existing biologics like Entyvio. The company has no marketed products and generates no product revenue; its worth is tied to clinical progress and the large addressable IBD market.

Full SYRE guide

ABBV vs SYRE: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ABBV drivers: Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine.
  • SYRE drivers: TL1A pipeline and the 2027 catalyst cadence; Differentiated long-acting dosing.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. For SYRE, spyre is pre-revenue and unprofitable, with net losses of about $264 million across the last four reported quarters, including $96.1 million in Q3 2026 as R&D spending roughly doubled to $89.2 million, and analysts expect losses of about $3.04 per share in 2026 and $3.69 in 2027 as trials scale, so the valuation rests entirely on future clinical success.

ABBV or SYRE: which should you pick?

If the story you believe is ABBV's (Skyrizi and Rinvoq replacing Humira faster than expected), ABBV is the more direct way to own it; if it is SYRE's (TL1A pipeline and the 2027 catalyst cadence), SYRE is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABBV and SYRE guides.

ABBV vs SYRE: the full fundamentals

ABBV. The gap between the trailing GAAP P/E (about 50x, inflated by non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 17.8x illustrates why analysts and management prefer adjusted metrics: upfront licensing and milestone payments depress reported earnings without reducing cash generation. The trailing multiple has fallen from about 80x in October as a strong Q3 GAAP quarter (about $4.2 billion of net income) replaced weaker ones, while the forward multiple has drifted up with the share price. The 26 covering analysts have a buy consensus and a mean target near $316.

SYRE. Spyre has no product revenue and posts steady losses funding R&D, so traditional earnings and valuation multiples do not apply. Its roughly $8.9 billion market cap (November 20, 2026) reflects expectations for its TL1A, IBD and newer dermatology pipeline, not current cash flow, and sits about 9x book value. Investors weigh a pro forma cash position near $1.47 billion and runway into the second half of 2029 against clinical milestones, the next large one being SKYLINE combination data in Q3 2027.

Headline figures (approximate, November 2026): ABBV shows revenue (ttm) ~$66.0 billion (Q3 2026 ~$17.4B, up ~10% YoY), adjusted eps Q3 2026 $3.82 vs $3.76 estimate; FY2026 consensus ~$13.98; FY2027 consensus ~$16.22, gaap net income (ttm) ~$10.3 billion (GAAP EPS ~$5.82, depressed by acquired IPR and D), margins (ttm) ~74% gross, ~37% operating, ~16% net; SYRE shows product revenue (ttm) ~$0 (clinical-stage), net loss (last four quarters) ~-$264M, eps (ttm) ~-$2.49, q3 2026 net loss ~-$96M (EPS -$0.94 vs ~-$0.84 est.).

The bottom line: ABBV vs SYRE

ABBV and SYRE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ABBV and SYRE exposure against your real portfolio. It is not an investment adviser.

Wondering how ABBV or SYRE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about AbbVie

Ask Walnut's AI anything about ABBV and see how it fits what you own.

FAQ

What is the difference between ABBV and SYRE?

+

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. Spyre Therapeutics (Nasdaq: SYRE) is a clinical-stage biotechnology company building extended half-life antibodies and antibody combinations aimed at inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and more recently the skin disease hidradenitis suppurativa (HS). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ABBV or SYRE the better stock?

+

Neither is universally better. ABBV is the larger incumbent; SYRE is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ABBV or SYRE?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ABBV and SYRE?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ABBV vs SYRE?

+

ABBV: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, about $81.3 billion as of September 2026 against about $10.8 billion of cash, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. GAAP earnings are depressed by acquired research charges, so the dividend exceeds trailing GAAP net income (a payout ratio near 117% of trailing GAAP EPS of about $5.82), and it is covered by cash flow rather than reported profit. Integrating acquisitions such as Apogee Therapeutics introduces execution risk, the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles, and after a 26% gain in 2026 the shares trade near their highs, though the mean analyst target has risen to about $316. SYRE: Spyre is pre-revenue and unprofitable, with net losses of about $264 million across the last four reported quarters, including $96.1 million in Q3 2026 as R&D spending roughly doubled to $89.2 million, and analysts expect losses of about $3.04 per share in 2026 and $3.69 in 2027 as trials scale, so the valuation rests entirely on future clinical success. Its programs are mostly early to mid-stage, and Phase 2 results do not guarantee Phase 3 or approval; SPY072's misses in the psoriatic arthritis and axial spondyloarthritis sub-studies of SKYWAY already closed off rheumatic diseases for that antibody. The TL1A space is intensely competitive, with Merck's tulisokibart already reporting registrational ulcerative colitis data and Roche, Sanofi/Teva, and others racing ahead, meaning Spyre may reach market later than established rivals. The stock is highly volatile (beta near 3, a 52-week range of about $23 to $111), and equity raises such as the October 2026 $350 million offering and at-the-market sales dilute holders. Any clinical, regulatory, or safety setback carries outsized downside for a company with no product sales.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABBV or SYRE; figures are approximate and dated (as of November 2026). Verify current data before investing.